Education
About Us
Working with TipRanks
Follow Us
VolitionRX (VNRX)
:VNRX
VNRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.40 - $0.94
Previous CloseN/A
Volume29.92K
Average Volume (3M)224.03K
Market Cap
$69.72M
Enterprise Value$85.42M
Total Cash (Recent Filing)$2.26M
Total Debt (Recent Filing)$10.94M
Price to Earnings (P/E)―
Beta0.10
Next Earnings
Nov 13, 2025EPS Estimate
-0.04Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.06
Shares Outstanding107,595,420
10 Day Avg. Volume245,211
30 Day Avg. Volume224,026
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.23
Enterprise Value/Revenue64.75
Enterprise Value/Gross Profit64.75
Enterprise Value/Ebitda-3.98
Forecast
1Y Price Target
$2.50Price Target Upside284.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Licensing OpportunitiesManagement expects to sign the company’s first agreement in the human diagnostics space, potentially comprising upfront and milestone payments as well as future recurring revenue.
Revenue GrowthPotential upfront and milestone payments, as well as future recurring royalties from agreements, are expected to drive Volition’s topline growth.
Strategic PartnershipsVolitionRx has entered an agreement with Hologic Diagenode for the co-marketing of Volition’s Nu.Q Discover service, aiming to expand its customer base.
Bears Say
Clinical And Market RisksRisks include failure in clinical development of diagnostic products, failure to secure license agreements, failure to achieve market traction, dilution risk, and going concern risk and delisting risk.
Financial RisksThe company may need to raise additional capital in the near term if sufficient cash is not received from the upcoming licensing deal.
VolitionRX News
VNRX FAQ
What was VolitionRX’s price range in the past 12 months?
VolitionRX lowest stock price was $0.40 and its highest was $0.94 in the past 12 months.
What is VolitionRX’s market cap?
VolitionRX’s market cap is $69.72M.
When is VolitionRX’s upcoming earnings report date?
VolitionRX’s upcoming earnings report date is Nov 13, 2025 which is in 37 days.
How were VolitionRX’s earnings last quarter?
VolitionRX released its earnings results on Aug 14, 2025. The company reported -$0.06 earnings per share for the quarter, missing the consensus estimate of -$0.054 by -$0.006.
Is VolitionRX overvalued?
According to Wall Street analysts VolitionRX’s price is currently Undervalued.
Does VolitionRX pay dividends?
VolitionRX does not currently pay dividends.
What is VolitionRX’s EPS estimate?
VolitionRX’s EPS estimate is -0.04.
How many shares outstanding does VolitionRX have?
VolitionRX has 107,595,420 shares outstanding.
What happened to VolitionRX’s price movement after its last earnings report?
VolitionRX reported an EPS of -$0.06 in its last earnings report, missing expectations of -$0.054. Following the earnings report the stock price went up 7.812%.
Which hedge fund is a major shareholder of VolitionRX?
Currently, no hedge funds are holding shares in VNRX
VolitionRX Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (284.62% Upside)
$2.50 (284.62% Upside)
Blogger Sentiment
Bullish
VNRX Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Bought Shares
Worth $109.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▲ 1.8%
Last 30 Days ▼ 17.2%
Last 30 Days ▼ 17.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-14.62%
12-Months-Change
Fundamentals
Return on Equity
138.92%
Trailing 12-Months
Asset Growth
-33.39%
Trailing 12-Months
Company Description
VolitionRX
VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose a range of cancers and other diseases worldwide. It sells Nu.Q that detect cancer; Nu.Q Nets, monitoring the immune system; Nu.Q Vet cancer screening test for veterinary applications; Nu.Q Capture capturing and concentrating samples for more accurate diagnosis; and Nu.Q Discover, a solution to profiling nucleosomes. The company operates Nucleosomics a technology platform for blood test. VolitionRx Limited is based in Austin, Texas.
VNRX Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant progress in cost reduction, revenue increase, and new product sales, alongside promising clinical study results. There was also strong progress in licensing and partnerships. However, concerns about uncertain revenue projections and decreasing cash reserves were noted.View all VNRX earnings summariesVNRX Stock 12 Month Forecast
Average Price Target
$2.50
▲(284.62% Upside)
Technical Analysis
Enzo Biochem
―
BioNano Genomics
―
Burning Rock Biotech
―
Biodesix
―
bioAffinity Technologies, Inc.
―
Ownership Overview
12.00% Insiders
2.11% Mutual Funds
18.98% Other Institutional Investors
65.92% Public Companies and
Individual Investors